Coherus Oncology, Inc.
NASDAQ:CHRSBiotechnology
+$0.03 today
- Market cap
- $63.35M
- Beta
- 0.96
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.11
Volume 2.55M
Average 1.15M
Returns on capital
Coherus Oncology, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-279.1%
avg 200.0%
ROIC
-151.8%
avg -103.3%
ROA
-65.9%
avg -63.3%
Analysis
ROA is currently the strongest return metric at -65.9% versus its period average of -63.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Dennis Lanfear | Chairman, President & Chief Executive Officer | USD 1.91M | 71 | — | — |
Sameer Goregaoker | Chief Commercial Officer | USD 854.06K | — | — | — |
Bryan J. McMichael | Chief Financial Officer | USD 788.89K | 47 | 0 | <0.01% |
Arvind Sood | Chief Strategy & Corporate Affairs Officer | — | — | — | — |
Michael Chen | Senior Vice President of Commercial Analytics & Trade | — | — | — | — |
Carrie Graham | Vice President of Investor Relations & Advocacy | — | — | — | — |
Rebecca Sunshine | Chief Human Resources Officer | — | 63 | — | — |
Andy Rittenberg | Chief Legal Officer | — | — | — | — |
Rosh Dias MRCP | Chief Medical Officer | — | 58 | — | — |
Theresa Lavallee | Chief Development Officer & Chairman of Scientific Advisory Board | — | 60 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 29, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -41.5% | +50.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -41.5% over three years. Forward estimates point to Revenue at +50.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Coherus Oncology, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about CHRS's management, answered from reported figures.
Who manages CHRS?
Coherus Oncology, Inc. (CHRS) lists 10 active executives. The top listed executive is Arvind Sood, Chief Strategy & Corporate Affairs Officer.
Are CHRS insiders buying or selling?
Recent insider activity shows net selling of $23.21M.
Continue the stock analysis
Jump to another research area for this company.